Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic …
Dec 13, 2022 · In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment...
Sustained benefit of zanubrutinib vs ibrutinib in patients with …
Dec 26, 2024 · The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis with extended follow-up.
An ALPINE guide to covalent BTKis in CLL
Dec 26, 2024 · The superior efficacy in ALPINE of zanubrutinib vs ibrutinib occurred across all parameters of PFS, at the index point of 36 months, and for the overall population was 65.4% vs 54.4%, for TP53 dysfunctional patients was 59.2% vs 38.5%, and for those on active treatment was a less marked difference of 78.7% vs 71.5%.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic ...
Nov 17, 2022 · ALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The primary end point …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic …
Jan 26, 2023 · In prespecified interim analyses, zanubrutinib was superior to ibrutinib with respect to overall response (the primary end point). Data from the final analysis of progression-free survival are now available.
Sustained benefit of zanubrutinib vs ibrutinib in patients with …
Dec 26, 2024 · Zanubrutinib is a uniquely designed BTKi specifically developed for greater BTK specificity and increased potency compared with ibrutinib and acalabrutinib. 3 With exposure coverage above the half-maximal inhibitory concentration during the entire dosing interval, 4 zanubrutinib can provide sustained BTK occupancy across disease-relevant ...
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic ...
Feb 10, 2023 · Zanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition.
ALPINE: After 39 Months, Zanubrutinib Keeps Its PFS Edge Over Ibrutinib …
Dec 9, 2023 · At 39 months, patients taking zanubrutinib after 1 prior treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia retained a 32% edge in progression-free survival (PFS) over...
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients
Sep 24, 2024 · ALPINE (NCT03734016) established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL); here we present data from the final comparative analysis with extended follow-up.
Comparison of Zanubrutinib and Ibrutinib As Treatments for …
Nov 5, 2024 · We report the first real-world, multicenter retrospective study comparing ibrutinib and zanubrutinib as treatment for WM implementing PSM to minimize bias. Mortality rate of ibrutinib treated patients was higher than that of zanubrutinib treated patients during almost three years of follow-up.
- Some results have been removed